INBXINBXHealthcare · Biotechnology

INBX Stock Forecast: Inhibrx Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$104
+4.52% on the day

The 3 Wall Street analysts covering Inhibrx Biosciences, Inc. hold a median 12-month price target of $278 — +167.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.5B
Ticker Nerd rank
26 / 100
Median analyst target
$278
Analysts covering
3
Total return, dividends reinvested
1W
+17.3%
1M
+18.3%
YTD
+31.2%
1Y
+328.9%
From 52W high
−26.9%
From 52W low
+328.9%
$24
$142
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INBX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inhibrx Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Accruals
66
Growth
54
Value
45
Size
40
Revisions
32
Issuance
18
Volatility
14
Quality
8

Momentum (91): The shares have been drifting up relative to others.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INBX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INBX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200$250$300$350Oct 25Jan 26Apr 26Jul 26INBXHigh $325Median $278Low $230

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $230Median $278High $325

The green dot is the last close — the median target sits +167.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Apr 2026StifelInitiatesBuy$150
8 Apr 2026StifelInitiatesBuy
22 Aug 2025JMP SecuritiesReiteratesMarket Perform
15 May 2025JMP SecuritiesReiteratesMarket Perform
18 Mar 2025Citizens Capital MarketsReiteratesMarket Perform
22 Jan 2025JMP SecuritiesReiteratesMarket Perform
23 July 2024JMP SecuritiesInitiatesMarket Perform
23 Jan 2024JMP SecuritiesDowngradeMarket Perform
20 Nov 2023JMP SecuritiesReiteratesMarket Outperform
23 Aug 2023JMP SecuritiesMaintainsOutperform
10 May 2023JMP SecuritiesReiteratesMarket Outperform
8 Mar 2023JMP SecuritiesMaintainsMarket Outperform
7 Mar 2023Credit SuisseReiteratesOutperform
8 Nov 2022Credit SuisseMaintainsOutperform
5 Oct 2022Evercore ISI GroupMaintainsOutperform
25 Aug 2022SMBC NikkoInitiatesOutperform
9 Aug 2022Credit SuisseMaintainsOutperform
16 Mar 2022SMBC NikkoInitiatesOutperform
2 Mar 2022JMP SecuritiesMaintainsMarket Outperform
10 Nov 2021Credit SuisseMaintainsOutperform

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INBX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

INBX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Inhibrx Biosciences, Inc. (INBX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
1173.2×

Cheaper than 1% of US stocks

Price / book
−76.7×

Cheaper than 99% of US stocks

EV / EBITDA
−12.5×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
Earnings growth (YoY)
Gross margin
Operating margin
−9835.2%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1773.6%

Higher than 1% of US stocks

Return on assets
−43.6%

Higher than 9% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

INBX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INBXInhibrx Biosciences, Inc.$1.5B
26
LBRXLB Pharmaceuticals, Inc.$1.5B
6
TYRATyra Biosciences, Inc.$1.5B
34
SLBTSL Science Holding Ltd.$1.5B
0
BCAXBicara Therapeutics, Inc.$1.6B
50
NVAXNovavax, Inc.$1.5B
54
ORICOric Pharmaceuticals, Inc.$1.5B
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inhibrx Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INBX news & analysis

Inhibrx Reports Second Quarter 2026 Financial Results

PRNewsWire · 13 Aug 2026neutral

Inhibrx Biosciences reported its financial results for the second quarter of 2026, noting that it has two programs in ongoing clinical trials.

Why it matters — The update provides a routine financial and operational checkpoint for a biopharmaceutical company with active clinical-stage programs.

FAQ

Frequently asked questions about INBX stock

What is the INBX stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Inhibrx Biosciences, Inc. have a median 12-month price target of $278, with estimates ranging from $230 to $325. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INBX stock a buy right now?

Of the 3 analysts covering Inhibrx Biosciences, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inhibrx Biosciences, Inc. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INBX?

As at 22 Aug 2026, Inhibrx Biosciences, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will INBX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +167.8% from the last close, and Ticker Nerd's factor model ranks Inhibrx Biosciences, Inc. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INBX stock forecast for 2030?

No analyst covering Inhibrx Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $230 to $325 over the next 12 months.

How has INBX stock performed over the past year?

Inhibrx Biosciences, Inc. returned +328.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inhibrx Biosciences, Inc. do?

Inhibrx Inc. is a biotechnology company that focuses on developing monoclonal antibodies used for treating a range of life-threatening diseases.

What is the latest news on INBX?

The most recent item we track (PRNewsWire, 13 Aug 2026): "Inhibrx Reports Second Quarter 2026 Financial Results". Inhibrx Biosciences reported its financial results for the second quarter of 2026, noting that it has two programs in ongoing clinical trials.

Company

About Inhibrx Biosciences, Inc.

Inhibrx Inc. is a biotechnology company that focuses on developing monoclonal antibodies used for treating a range of life-threatening diseases. The company’s primary objective is to innovate targeted therapies that can address significant unmet medical needs in the areas of oncology, rare diseases, and autoimmune conditions. Notably, Inhibrx leverages its proprietary single-domain antibody technology platform to engineer highly differentiated biological therapies. By concentrating on precision medicine, the firm's approach aims to deliver more effective solutions with the potential for enhanced patient outcomes as compared to traditional treatments. Operating in the burgeoning biotechnology sector, Inhibrx contributes to the advancement of medical research and the development of targeted therapies. The company's role in the financial market encompasses that of a high-growth potential entity, attracting interest from investors focused on cutting-edge healthcare innovations and the broader biotechnology industry developments.

CEO Mr. Mark Paul Lappe · 109 employees · United States · https://inhibrx.com